DB05840ExperimentalSmall molecule
AGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to address the accelerated inflammation of grafted blood vessels, known as transplant arteritis, common in chronic...
- Mechanism
- Curator reviewed
AGI-1096 is a novel phenolic intracellular antioxidant with anti-inflammatory and antiproliferative properties.
- Primary indication
- Investigated for use/treatment in transplant (rejection).Curator reviewed
- Code names
- AGI-1096
Resolves to
Compound
What you can answer from here — as of October 27, 2025
Which companies are running trials of Elsibucol, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account